Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Advertisement
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

US Drug Pricing Reform: No More Medicare 'Gravy Train,' Azar Tells Pharma

HHS secretary urges serious proposals from biopharma on enhancing price negotiation in Medicare Parts D and B, promising action from the Administration whether the industry cooperates or not.

Pricing Debate Medicare

CAR-T Therapy In Medicare: National Coverage Policy Could Come In 2019

Medicare begins analysis process for CAR-T cancer therapies in response to a request from UnitedHealthcare for a national coverage policy.
Medicare Cancer

Part B Drug Competitive Bidding Program Revival: Vendor Request Coming Soon

Distributors, specialty pharmacies and PBMs are in a better position now to act as vendors then they were a decade ago, when Medicare unsuccessfully tried to implement a Medicare Part B prescription drug competitive acquisition program, HHS Secretary Azar points out.

Pricing Debate Medicare

Pricing Positives From Trump Plan Include Potential 340B Changes, Value-Based Contracts

Industry should be encouraged by Blueprint's interest in examining impact of Medicaid rebates, the annual excise tax, and the 340B program. Document also confirms Administration’s interest in value-based contracting.

Pricing Debate Policy

'Immediate' Steps To Lower Drug Prices: The HHS Action Plan

Many of US drug pricing blueprint's proposals could be accomplished administratively, but will still be shaped by stakeholder feedback.

Pricing Debate Medicare

'Immediate' Steps To Lower Drug Prices: The HHS Action Plan

Many of blueprint's proposals could be accomplished administratively, but will still be shaped by stakeholder feedback.

Pricing Debate Medicare
See All
Advertisement
UsernamePublicRestriction

Register